An observational study in Choledocholithiasis, Biliary Stricture and Chronic Pancreatitis, sponsored by Institute of Liver and Biliary Sciences, India. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Institute of Liver and Biliary Sciences, India · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
ERCP is a fluoroscopy procedures are associated with significant radiation exposure to patients. Radiation exposure is associated with adverse effects both short term and long term which might negatively impact the quality of life of the patient. The effects of radiation maybe deterministic or stochastic the effects may range from mild such as skin irritation to long term effects such as cancer. Hence there is a need to limit the dosage of radiation exposed to the patient. Therefore, there is a need to establish standard reference levels. Radiation is measured in Dose Area Product (DAP), Effective dose (ED), Reference air Kerma (Ka,r). The radiation exposure is measured for the patients undergoing ERCP from January 2023 to Dec 2025 will be collected. DRLs will be calculated for these metrics. DRL is 3rd quartile of the measured values. The dosage of radiation which the patient receives depends on several factors such as patients BMI, position, complexity of the procedure and several other factors. As a secondary objective several factors affecting the radiation exposure is also noted.
109 studies on the registry are indexed under Choledocholithiasis; 24 are open to participants now.
This study's planned enrollment of 150 is below the median of 200 across 31 observational studies indexed under Choledocholithiasis.
Browse Choledocholithiasis studies →Institute of Liver and Biliary Sciences, India is the lead sponsor of 303 studies on the registry; 88 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All consecutive in-patients and out-patients undergoing ERCP .
Inclusion Criteria: • Patients Undergoing ERCP -
Exclusion Criteria: Patients with missing dosimetry data
-
Estimate the distribution of total radiation dose (median, IQR, 75th percentile) reflected by DAP (Gy·cm²) for ERCP and propose local DRLs.
Time frame: Day 0
- Estimation of Diagnostic reference (DRLs) -(median, IQR, 75th percentile)for ERCP procedures for Ka,r (in mGy) , FT (in min),ED(in mSv).
Time frame: Day 0
- Patient's fluoroscopy time (in min), reference air-kerma (in mGy), and number of acquisitions(n) will be measured
Time frame: Day 0
- Correlation of DAP and Ka,r with ASGE complexity grade, HOUSE grading, Stanford fluoroscopy complexity scores will be done using Spearman rank correlation coeffecient
Time frame: Day 0
- Track proportion of cases exceeding candidate DRLs or published reference values to guide procedure optimization.
Time frame: Day 0
Multivariate regression will be used for correlation of procedure indication, BMI(kg/m²), prior sphincterotomy(yes/no), trainee involvement (yes/no), collimation(yes/no), and image acquisitions with DAP(Gy·cm²) and Ka,r (in mGy)
Time frame: Day 0
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2026, 0 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Liver and Biliary Sciences, India →